Morningstar: Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
In one form of pulmonary hypertension, called pulmonary arterial hypertension (PAH), blood vessels in the lungs are narrowed, blocked or destroyed. The damage makes it hard for blood to move through the lungs.
Pulmonary arterial hypertension (PAH) is a narrowing of the small blood vessels in your lungs. Causes include connective tissue diseases and genetic mutations.
With PAH, you have high blood pressure in the arteries that go from your heart to your lungs. You may have symptoms such as shortness of breath, swelling, and chest pain, among other signs.
Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension, which means high blood pressure in the lungs. Understand what PAH is, symptoms and risk factors for PAH, how it's treated and more.
Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle ...
The PAH Initiative (PAH-I), sponsored by United Therapeutics, is committed to providing knowledge and inspiration to people with pulmonary arterial hypertension (PAH).
Abstract Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death.
In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly...